vernakalant
DISEASE INTERVENTION COMPARISON RESULTS
Circ Arrhythm Electrophysiol. 2011 Oct;4(5):637-43 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, paroxysmal, Study ID: Torp-Pedersen 2011 The Use of
vernakalant
As Treatment, Chronic
Is better Than
placebo
To reduce AF recurrence at 3 months, at the cost of several serious events associated (3 patients)
Circulation. 2008 Mar 25;117(12):1518-25 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, recent onset The Use of
vernakalant
As Treatment, Acute
Is better Than
placebo
To acute, rapid cardioversion to sinus rhythm: 38 to 52 % vernakalant VS 3 to 4% placebo.